Merck's Keytruda Chemo-Combo Data Has Big Implications For Future Of Immuno-Oncology
Merck’s strong Phase II data testing Keytruda with chemotherapy in first-line lung cancer may put pressure on future IO/IO combinations when it comes to toxicity, efficacy and – importantly – cost.
You may also be interested in...
Lilly’s new CEO David Ricks said he had confidence in the Trump Administration’s ability to understand and respond to the biopharma industry’s needs as well as address drug pricing concerns. The company’s fourth quarter earnings could insulate it from cost criticism, since sales volume drove revenue gains, not prices.
Facing analysts jittery about the prospects for Opdivo/Yervoy in first-line lung cancer, Bristol boasts breadth of Phase III lung program, including IO/chemo studies, and variety of tumor types targeted.
Bristol's filing of Yervoy/Opdivo in first-line lung cancer is delayed as the company drops its plans for accelerated approval, but could be on a more solid regulatory footing if the pivotal trial is successful. Meanwhile, AstraZeneca is using adaptive trial design to update MYSTIC, which could result in broader approvals.